News

Results Found (492)
April 6, 2008
Yissum spin-off CollPlant raises $8.3m

The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.

 

March 23, 2008
Forbes- Celebrating Israel's 60th Anniversary (Hebrew)

Nava Swersky Sofer congratulating Israel on it's 60th anniversary on a special Forbes edition. 

March 22, 2008
Health Scan: Hebrew U. makes genetic database available

The unique case-controlled DNA database for genetic association studies will allow the scientific community to access DNA samples directly via the Internet (www.hugr.org) and test genes of interest.

March 11, 2008
Yissum Announces the Launch of the Hebrew University’s Genetic Resource...

The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

February 28, 2008
Yissum Announces the Discovery of a Novel Small Molecule with Potent...

Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers. 

February 13, 2008
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability...

Yissum spin-off Morria Biopharmaceuticals,  a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients...

January 28, 2008
Look what can be achieved with three molecules and one communication technology

Globes article portraying Israeli Technology Transfer (Hebrew)

January 22, 2008
Protalix BioTherapeutics Extends Research Agreement With Yissum, Based on...

The Acetylcholinesterase (AChE) Program is being conducted

under the agreement the Company entered into with Yissum Research and

Development Company, the technology transfer arm of the Hebrew University of

Jerusalem, Israel, and the Boyce...

January 22, 2008
Israel's most powerful woman in biotech

Israel 21c portraying Nava Swersky Sofer, Yissum's President & CEO 

January 13, 2008
Yissum spin-off Biocancell to begin Phase IIb trial for bladder cancer drug

The FDA approved the trial at 5 Israeli hospitals and one in Arizona. 

 

January 9, 2008
New Alzheimer's drug to go commercial, thanks to Israeli research

Yissum and Eucalyptus Biosciences Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

December 28, 2007
Ivory Towers? Not!

Israel's Universities and institutes are all about developing and selling technology